Influence of blood group and von Willebrand factor on population pharmacokinetics and dose individualization of recombinant factor VIII in Taiwanese patients with haemophilia A.
Noppaket SingkhamBaralee PunyawudhoMing-Sun YuShin-Nan ChengShu-Huey ChenHung ChangChih-Cheng ChenChih-Cheng HsiaoJen-Yin HouYi-Ping FangHsiang-Wei WangJia-Hong LinLennex Hsueh-Lin YuYeu-Chin ChenPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2022)
The population PK of rFVIII was successfully developed. Dose adjustment based on blood type and VWF level should be considered.
Keyphrases